BACKGROUND: Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined. We, therefore, studied the relationship between severity of anemia and outcome in myelodysplastic syndrome patients. DESIGN AND METHODS: We studied 840 consecutive patients diagnosed with myelodysplastic syndromes at the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, and 504 patients seen at the Heinrich-Heine-University Hospital, Düsseldorf, Germany. Hemoglobin levels were monitored longitudinally and analyzed by means of time-dependent Cox's proportional hazards regression models. RESULTS: Hemoglobin levels lower than 9 g/dL in males (HR 5.56, P=0.018) and 8 g/dL in females (HR=5.35, P=0.026) were independently related to reduced overall survival, higher risk of non-leukemic death and cardiac death (P<0.001). Severe anemia, defined as hemoglobin below these thresholds, was found to be as effective as transfusion-dependency in the prognostic assessment. After integrating this definition of severe anemia into the WHO classification-based Prognostic Scoring System, time-dependent regression and landmark analyses showed that the refined model was able to identify risk groups with different survivals at any time during follow up. CONCLUSIONS: Accounting for severity of anemia through the WHO classification-based Prognostic Scoring System provides an objective criterion for prognostic assessment and implementation of risk-adapted treatment strategies in myelodysplastic syndrome patients.
BACKGROUND:Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined. We, therefore, studied the relationship between severity of anemia and outcome in myelodysplastic syndromepatients. DESIGN AND METHODS: We studied 840 consecutive patients diagnosed with myelodysplastic syndromes at the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, and 504 patients seen at the Heinrich-Heine-University Hospital, Düsseldorf, Germany. Hemoglobin levels were monitored longitudinally and analyzed by means of time-dependent Cox's proportional hazards regression models. RESULTS: Hemoglobin levels lower than 9 g/dL in males (HR 5.56, P=0.018) and 8 g/dL in females (HR=5.35, P=0.026) were independently related to reduced overall survival, higher risk of non-leukemic death and cardiac death (P<0.001). Severe anemia, defined as hemoglobin below these thresholds, was found to be as effective as transfusion-dependency in the prognostic assessment. After integrating this definition of severe anemia into the WHO classification-based Prognostic Scoring System, time-dependent regression and landmark analyses showed that the refined model was able to identify risk groups with different survivals at any time during follow up. CONCLUSIONS: Accounting for severity of anemia through the WHO classification-based Prognostic Scoring System provides an objective criterion for prognostic assessment and implementation of risk-adapted treatment strategies in myelodysplastic syndromepatients.
Authors: Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb Journal: Blood Date: 2007-09-14 Impact factor: 22.113
Authors: W H Wilson Tang; Wilson Tong; Anil Jain; Gary S Francis; C Martin Harris; James B Young Journal: J Am Coll Cardiol Date: 2008-02-05 Impact factor: 24.094
Authors: Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl Journal: Blood Date: 2007-08-28 Impact factor: 22.113
Authors: Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Anna Paola Iori; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Luca Malcovati; Cristiana Pascutto; Rosi Oneto; Renato Fanin; Alberto Bosi Journal: Blood Date: 2008-05-22 Impact factor: 22.113
Authors: Martin Jädersten; Luca Malcovati; Ingunn Dybedal; Matteo Giovanni Della Porta; Rosangela Invernizzi; Scott M Montgomery; Cristiana Pascutto; Anna Porwit; Mario Cazzola; Eva Hellström-Lindberg Journal: J Clin Oncol Date: 2008-06-16 Impact factor: 44.544
Authors: M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola Journal: Leukemia Date: 2015-02-27 Impact factor: 11.528
Authors: S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost Journal: Leukemia Date: 2015-07-08 Impact factor: 11.528
Authors: Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick Journal: Cancer Epidemiol Date: 2015-02-18 Impact factor: 2.984